Datum | Källa | Rubrik | Typ | Alternativ | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-11 | Nanexa | First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-06-11 | Nanexa | Första patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-15 | Nanexa | Kommuniké från årsstämma i Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-15 | Nanexa | Bulletin from Nanexa’s Annual General Meeting | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-15 | Nanexa | Nanexa receives approval for NEX-22 clinical study | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-15 | Nanexa | Nanexa erhåller godkännande för klinisk studie med NEX-22 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-10 | Redeye | Redeye: Nanexa Q1 2024 - Insightful capital markets day | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-10 | Emergers | Emergers: Equity Research | NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-03 | Nanexa | Nanexa publishes interim report for January-March 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-05-03 | Nanexa | Nanexa publicerar delårsrapport för januari-mars 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-30 | Nanexa | Invitation to comment on Nanexa's Q1 report 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-30 | Nanexa | Inbjudan till kommentar av Nanexas Q1-rapport 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-29 | Nanexa | Nanexa invites to Capital Markets Day on May 7 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-29 | Nanexa | Nanexa bjuder in till kapitalmarknadsdag 7 maj | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-16 | Nanexa | Godkännandet av klinisk prövningsansökan för NEX-22-studien försenas | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-16 | Nanexa | Approval of clinical trial application for NEX-22 study delayed | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-04-15 | Nanexa | Notice of annual general meeting in Nanexa AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
Pressreleaser |
Notice of annual general meeting in Nanexa AB (publ)The shareholders in Nanexa AB (publ), reg.no 556833–0285 (the ”Company”) are hereby given notice that the annual general meeting will be held on Wednesday 15 May 2024, at. 3:00 pm, at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden. Rights to participate at the general meeting
The notification must state the shareholder’s name, personal or corporate identity number, address, telephone number, shareholding, information about any assistants and, where applicable, information about representatives or proxies. Nominee-registered shares Proxy Number of shares and votes Proposed agenda Resolution proposal Item 1 – Opening of the meeting and election of the chairman for the meeting The nomination committee for the 2024 has consisted of Marlon Värnik, (appointed by Exelity AB), Christian Östberg (appointed by Gerhard Dal) and Göran Ando (chairman of the board), co-opted. Item 8b) – Dispositions regarding the Company’s result according to the approved balance sheet Item 9 – Determination of remuneration to the board of directors and the auditor Item 10 – Election of the board of directors and auditor The nomination committee proposes that Göran Ando is re-elected as chairman of the board. Hanna Tilus is a lawyer and partner at Cirio Advokatbyrå. Hanna has over fifteen years of experience in the life science industry, in particular pharmaceuticals and medical technology. Her areas of expertise include commercial agreements, license arrangements, patent litigation and regulatory issues. Her previous experience includes 4.5 years as in-house counsel at Bayer where she mainly worked in the Nordic region but also at the German headquarters. Hanna holds a law degree and a Bachelor of Philosophy degree with a major in psychology from Stockholm University. The nomination committee proposes re-election of Öhrlings PricewaterhouseCoopers AB as auditor. Chartered accountant Niclas Bergenmo will in such a case continue as principal auditor. Item 11 – Establishment of a nomination committee and adoption of instructions for the nomination committee The general meeting instructs the chairman of the board to contact the three largest shareholders in terms of votes according to Euroclear Sweden AB’s printout of the share register as of 30 September 2024, who each appoint a member of the nomination committee. In the event that any of the three largest shareholders does not wish to appoint a member of the nomination committee, the fourth largest shareholder shall be consulted and so on until the nomination committee consists of three members. However, not more than ten shareholders need to be consulted. Furthermore, the chairman of the board shall be co-opted to the nomination committee. The members of the nomination committee shall be published on the Company’s website no later than six months before the next annual general meeting. The term of office for the appointed nomination committee shall run until a new nomination committee has been appointed in accordance with the mandate from the next annual general meeting. The nomination committee appoints a chairman from among its members. The chairman of the board or another board member shall not be the chairman of the nomination committee. If a member leaves the nomination committee before its term is completed, and if the nomination committee considers that there is a need to replace this member, the nomination committee shall appoint a new member in accordance with the principles above, but based on Euroclear Sweden AB’s printout of the share register as soon as possible after the member has left its post. Changes in the composition of the nomination committee shall be announced immediately. No remuneration shall be paid to the committee members for their work on the nomination committee. The Company shall however bear reasonable costs that arise in the nomination process. The nomination committee shall submit proposals for resolutions on the following issues to the 2025 annual general meeting: Item 12 – Resolution on amendment of the Company’s articles of association
The CEO, or any other person appointed by the board of directors, shall have the right to make such minor adjustments to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office and Euroclear Sweden AB. A resolution in accordance with the proposal requires that the resolution is supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting. Item 13 – Resolution on authorization (rights issue) Item 14 – Resolution on authorization (directed issue) The reason to propose that the board of directors shall be authorized to resolve on issues with deviation from the shareholder’s pre-emption rights, with or without provisions on payment by non-cash consideration, by way of set-off or other provisions in accordance with above is that the Company shall be able to issue shares, warrants and/or convertible instruments with the purpose of acquiring new capital and for the board of directors to direct issues to investors that the board of directors deems to be strategically important for the Company. A resolution in accordance with the proposal requires that the resolution is supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting. Processing of personal data Questions to the board of directors and the managing director Provision of documents Uppsala in April 2024 Nanexa AB (publ) The Board of Directors |
||||||||||||||
2024-04-15 | Nanexa | Kallelse till årsstämma Nanexa AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-03-27 | Nanexa | Nanexa publicerar årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-03-27 | Nanexa | Nanexa publishes annual report for 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-02-22 | Redeye | Redeye: Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-02-22 | Emergers | Emergers: Equity Research | NANEXA: Focus on dual GLP-1 opportunities and the partner projects | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-02-21 | Nanexa | Nanexa publishes year-end report and Q4 report 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-02-21 | Nanexa | Nanexa publicerar bokslutskommuniké och Q4-rapport 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-02-20 | Nanexa | Invitation to presentation of Nanexa's year-end report and Q4 report 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2024-02-20 | Nanexa | Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-12-21 | Emergers | Emergers: Equity Research | NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-12-20 | Nanexa | Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-12-20 | Nanexa | Nanexa optimizes business operations through tactical priorities | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-12-20 | Nanexa | Nanexas kliniska prövningsansökan för NEX-22 fas I-studie emottagen av EMA | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-12-20 | Nanexa | Nanexa optimerar affärsverksamheten genom taktiska prioriteringar | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-30 | Nanexa | Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-30 | Nanexa | Nanexa byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-29 | Nanexa | Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-29 | Nanexa | Nanexa signs evaluation agreement with a large global pharmaceutical company | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-21 | Redeye | Redeye: Nanexa Q3 - Focused approach | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-21 | Emergers | Emergers: Equity Research | NANEXA: Raising our LOAs following a review of the projects | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-20 | Nanexa | Nanexa publishes interim report for January – September 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-20 | Nanexa | Nanexa publicerar delårsrapport för januari-september 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-14 | Nanexa | Nanexa presenterade hälsoekonomiska data på internationell kongress | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-14 | Nanexa | Nanexa presented Health Economical data at international conference | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-11-01 | Emergers | Emergers: Equity Research | NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-30 | Nanexa | Nanexa offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-30 | Nanexa | Nanexa announces outcome of rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-20 | Nanexa | Nanexa erhåller ytterligare teckningsförbindelse i pågående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-20 | Nanexa | Nanexa receives additional subscription undertaking in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-11 | Nanexa | Nanexa publishes EU growth prospectus in connection with rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-11 | Nanexa | Nanexa offentliggör EU-tillväxtprospekt med anledning av företrädesemission | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-11 | Nanexa | Nanexa reports preliminary key financial information for the period January-September 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-11 | Nanexa | Nanexa rapporterar preliminär finansiell nyckelinformation för perioden januari-september 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-11 | Emergers | Emergers: Equity Research | NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-05 | Nanexa | Nanexa completes clinical phase I study with NEX-20 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-10-05 | Nanexa | Nanexa har slutfört den kliniska fas I-studien med NEX-20 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-28 | Nanexa | Nanexa bjuder in till investerarmöte 9 oktober i Uppsala | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-28 | Nanexa | Nanexa invites to investor meeting on October 9th in Uppsala | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-22 | Nanexa | Invitation to commentary regarding rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-22 | Nanexa | Inbjudan till kommentar gällande företrädesemission | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-22 | Emergers | Emergers: NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-21 | Nanexa | Nanexa carries out a rights issue of approximately SEK 121 million | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-21 | Nanexa | Nanexa genomför en företrädesemission om cirka 121 MSEK | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-06 | Nanexa | Nanexa presenterar vid ISPOR Europe 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-09-06 | Nanexa | Nanexa presents at ISPOR Europe 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-30 | Nanexa | Nanexa beviljas patent i Indien | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-30 | Nanexa | Nanexa is granted patent in India | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-24 | Redeye | Redeye: Nanexa Q2 - Solid progress but a capital injection is on the horizon | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-24 | Emergers | Emergers: Equity Research | NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-23 | Nanexa | Nanexa publicerar delårsrapport för januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-23 | Nanexa | Nanexa publishes interim report for January – June 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-22 | Nanexa | Invitation to presentation of Nanexa’s Q2 report 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-22 | Nanexa | Inbjudan till presentation av Nanexas Q2-rapport 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-22 | Nanexa | Nanexa bekräftar fortsatt positiva resultat från en ny preklinisk studie av NEX-22 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-22 | Nanexa | Nanexa confirms continued positive results from a new preclinical study of NEX-22 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-22 | Nanexa | Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-08-22 | Nanexa | Nanexa erhåller farmakokinetiska data från den kliniska fas I-studien med NEX-20 som konfirmerar kontrollerad frisättning av lenalidomid | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-07-10 | Nanexa | Summer letter from Nanexa | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|
||||||||||||||
2023-07-10 | Nanexa | Sommarbrev från Nanexa | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||
|